1. Signaling Pathways
  2. PI3K/Akt/mTOR
  3. mTOR
  4. mTOR Isoform
  5. mTOR Inhibitor

mTOR Inhibitor

mTOR Inhibitors (113):

Cat. No. Product Name Effect Purity
  • HY-13003
    Torin 1
    Inhibitor 98.95%
    Torin 1 is a potent inhibitor of mTOR with an IC50 of 3 nM.
  • HY-10422
    AZD-8055
    Inhibitor 99.60%
    AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM.
  • HY-50673
    Dactolisib
    Inhibitor 99.94%
    Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC50s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively.
  • HY-13328
    Sapanisertib
    Inhibitor 99.66%
    Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
  • HY-13002
    Torin 2
    Inhibitor 99.98%
    Torin 2 is an mTOR inhibitor with EC50 of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC50: 200 nM).
  • HY-10474
    Torkinib
    Inhibitor 98.37%
    Torkinib (PP 242) is a selective and ATP-competitive mTOR inhibitor with an IC50 of 8 nM.
  • HY-15247
    Vistusertib
    Inhibitor 98.21%
    Vistusertib (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM.
  • HY-111373
    RapaLink-1
    Inhibitor ≥98.0%
    RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker.
  • HY-100542
    D-α-Hydroxyglutaric acid disodium
    Inhibitor ≥98.0%
    D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria.
  • HY-15177
    PF-04691502
    Inhibitor 99.64%
    PF-04691502 is a potent and selective inhibitor of PI3K and mTOR.
  • HY-12513
    Samotolisib
    Inhibitor 99.42%
    Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively.
  • HY-139609
    Camonsertib
    Inhibitor 99.75%
    Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays.
  • HY-124798
    Rheb inhibitor NR1
    Inhibitor 99.46%
    Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay.
  • HY-15174
    Dactolisib Tosylate
    Inhibitor 99.88%
    Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively.
  • HY-N0047
    Polyphyllin I
    Inhibitor 99.61%
    Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity.
  • HY-10683
    PKI-402
    Inhibitor 98.43%
    PKI-402 is a selective, reversible, ATP-competitive inhibitor of PI3K, including PI3K-α mutants, and mTOR (IC50=2, 3, 7,14 and 16 nM for PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ).
  • HY-10681
    Gedatolisib
    Inhibitor 99.68%
    Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively.
  • HY-15900
    Voxtalisib
    Inhibitor 99.46%
    Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43 nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150 nM) and mTOR (IC50=157 nM).
  • HY-12868
    Bimiralisib
    Inhibitor 98.74%
    Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively.
  • HY-10423
    OSI-027
    Inhibitor 99.40%
    OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive mTOR kinase activity inhibitor with an IC50 of 4 nM.